Randomized trial of rhDNase for treatment of cystic fibrosis
Note! A few subjects were infected at the time of enrollment, 951317 for
instance has a first infection interval of -21 to 7. We do not count this
first infection as an "event", and the subject first enters the risk set
at day 7.
- subject id
- treatment arm: 0=placebo, 1=rhDNase
- FEV: "forced expiratory volume", a measure of lung capacity
- FEV2: a second measurement of FEV
- randomization date
- last follow-up date on study
- infections: there are up to 5 infections, each is a pair of numbers,
e.g., "90 104" shows that a patient had a lung infection and
was on antibiotic therapy from day 90 to 104.
sample SAS code to read the data
Reference: TM Therneau and SA Mamilton,
"rhDNase as an example of recurrent event analysis", Statistics
in Medicine, vol 16, 2029-2047, 1997.
To our embarrassment, we cannot exactly reproduce the numbers in the
paper. There are multiple ways to define an infection, the number of
endpoints and exact timing of them changed at times during the
analysis, and we didn't save copies of the relevant data. (For
instance, does an infection start with oral antibiotic or is IV
antibiotic required?) None of the substantive conclusions is changed;
this data set gives the results in the book.